Furthermore, to treat HCC, Zuo et al. (75) developed novel PEGylated poly (lactic-co-glycolic acid) nanoparticles (PLGA-PEG NPs) loaded with si-LINC00958 targeting LINC00958, which is otherwise upregulated and stabilized by METTL3-mediated m6A modification, which promotes HCC progression. Here, LINC00958 is linked to hepatocellular carcinoma.